What Does ABPI Have To Say About NICE Proposals?

Catchpole welcomes the concept put forth in these new NICE proposals on value based assessment criteria, but says it’s too early to understand the full impact they will have on future medicines access. Read more here. (Source: FirstWord Pharma, 1/10/14).

You might also be interested in:

Trump White House Defends Plan to Cut Drug Prices May 15, 2018
Gottlieb’s Full Statement on New FDA Efforts to Prop… June 14, 2018
CVS Caremark’s Foray into Cost-Effectiveness Analysis… September 25, 2018
Orphan Drugs: European Payer Perspectives October 14, 2018
Real World Data Capabilities: Benchmarking Pharma Companies October 30, 2018
Syndicated Reports Spotlight RA, Type 2 Diabetes Mellitus January 15, 2018
Blockchain: Transformational Change for Pharma? August 14, 2018